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384 Long-term treatment with Pulmozyme® is associated with slower
rate or improvement of lung functions decline in CF patients
H. Kayserova. CCF, Dept. of Immunology, Faculty Hospital of Bratislava,
Bratislava, Slovakia
RhDNA-ase (Pulmozyme®) is used in the treatment in our patients since 1996.
Currently 114 patients are on the chronic treatment with rhDNA-ase (39.5% of CF
pts. on Slovak National Registry). 11 patients died in this period on respiratory or
liver failure.
Methods: Longterm follow-up study of 84 CF patients aged 5−48 years, treated
more than 10 years.
Patients were divided in three groups according to their initial FEV1 value:
group A: (n = 13, mean age 17.2 yrs) with FEV1< 60% p.v. Group B (n = 23, mean
age 12.6 yrs) with 60% <FEV180%. In group A mean FEV1 showed continous
improvement from 49% at the beginning of the treatment to 78% pred., in group B
from 69% to 84% pred., and in group C from 95% to 99% pred. after 10 years on
rhDNA-ase treatment. Similar trends showed other relevant lung function parameters
(FVC, PEF, MEF50). Decrease of exacerbations of the disease, changes in the
chronic colonisation (Pseudomonas sp.), and the improvement of the quality of life
in our patients have been observed.
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Aims: The ﬂuoroquinolone group of antibiotics are known to cause cutaneous
phototoxic reactions. The incidence of this phenomenon secondary to ciproﬂoxacin
in the general population is low (2−3%), however a previous pilot study carried
out by our team revealed the incidence to be increased in a sub group of patients
with cystic ﬁbrosis (CF). The aim of this study was to determine the incidence of
phototoxic skin reactions in the adult CF population of Northern Ireland.
Methods: We conducted this study using an interview-based questionnaire in
unselected adult CF patients during their routine clinic appointments.
Results: 105 patients were interviewed. 48 patients, 31 male and 17 female,
described getting a rash on photo-exposed sites after taking ciproﬂoxacin. 33 of
these patients did state that they had been given information and advice about
this side effect before taking the medication. The commonest genotype of those
affected was DF508/DF508 (23 patients), followed by DF508/G551D (3 patients),
DF508/621+1G→T (2 patients) and DF508/R117H (2 patients). In 11 patients the
genotype was either not determined or fully conﬁrmed. The further 9 patients had
other less common genotypes.
Conclusions: This study has revealed a 46% incidence of reported phototoxic
reactions secondary to ciproﬂoxacin in our adult CF population. This is signiﬁcantly
higher than that previously reported for the general population. It is important that
patients are fully counselled regarding this potential side effect.
Supported by: The Research and Development Ofﬁce, Northern Ireland.
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Tobramycin, with cochleotoxicity as one of its major side-effects, is frequently
prescribed in CF patients. The prevalence of cochleotoxicity due to tobramycin
exposure in Cystic Fibrosis patients is investigated.
In this retrospective cohort study all performed audiograms were obtained from
CF patients from the Haga Teaching hospital Adult CF centre. Collected were Pure
Tone Audiometry (PTA) and High Frequency Audiometry (HFA) data. Cochleotox-
icity was deﬁned as at least one frequency showing >20 dB increase in hearing
threshold uni- or bilaterally. All results were corrected for age and test-variability
(10 dB).
Eighty Patients (80/193 = 41.5%) were reported to be treated with at least one period
of systemically administered tobramycin. Thirty-two patients (33/80 = 41.3%) had
at least one PTA and HFA. Cochleotoxicity was reported in 13 out of 27 patients
(13/27 = 48.1%, 95% CI: 29.3−67.0%) The prevalence in the lower frequencies
(8 kHz) was 25.1% (7/27 = 25.1% (95% CI: 9.4 – 42.5%). The correlation between
the increase in hearing threshold and the cumulative exposure to tobramycin (AUC)
was positive, but not signiﬁcant. There was no difference in cochlear sensitivity to
tobramycin exposure between the right and left ear (p 0.001).
In conclusion, the prevalence of cochleotoxicity due to tobramycin exposure was
reported in 48.1% of the CF patients measured by HFA. Standard PTA detected
signiﬁcant less patients with cochleotoxicity. As a consequence, guidelines for High
Frequency Audiometry screening in clinical practice is necessary.
387 Vestibulotoxicity as a consequence of systemically administered
tobramycin in Cystic Fibrosis patients
R.J. Scheenstra1, E. Rijntjes1, D.L. Tavy2, H. Kingma3, H.G. Heijerman4.
1Otorhinolaryngology, Haga Teaching Hospital, The Hague, Netherlands;
2Clinical Neurophysiology, Haga Teaching Hospital, The Hague, Netherlands;
3Otorhinolaryngology, University Hospital Maastricht, Maastricht, Netherlands;
4Pulmonology, Haga Teaching Hospital, The Hague, Netherlands
Background: Tobramycin is a frequently prescribed aminoglycoside antibiotic in
CF patients. One of its major side-effects of is ototoxicity. Although CF patients
are routinely screened on cochleotoxicity, vestibulotoxicity is much less familiar
in clinical practice. As it has not been prospectively investigated in CF patients,
the prevalence of vestibulotoxicity due to tobramycin exposure in Cystic Fibrosis
patients is studied.
Methods: In this prospective study, patients from the Haga Teaching hospital Adult
CF center with at least one treatment with systemically intravenous tobramycin
were given a questionnaire, physical examination for peripheral vestibular disorders.
Finally, Electronystagmography with caloric irrigation was performed.
Results: Peripheral vestibular loss was found in 4 out of 21 patients (19.0%; 95% CI
2.20−35.8%). In one patient, central vestibular loss was reported. Preliminary results
of the questionnaire show that 47.6% (10/21) of the patients reported some degree
of whether dizziness or disturbance of the equilibrium. One patient with abnormal
ENG did not report any complaints of dizziness in the questionnaire.
Discussion: The reported prevalence of vestibulotoxicity (19%) in CF patients is
much higher than other authors reported in the general population (1.9−11%).
This may be caused by the frequently given doses of systemically administered
tobramycin in CF patients. Although these results are based on a small number of
patients, they indicate for screening for vestibulotoxicity in CF patients in the case
of tobramycin exposure.
